You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • SAT0174 Use of a 8-week observational period for predicting remission and low disease activity at 52 weeks in ra patients treated with certolizumab pegol – a multicenter study

Article info

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
SAT0174 Use of a 8-week observational period for predicting remission and low disease activity at 52 weeks in ra patients treated with certolizumab pegol – a multicenter study
Free

Authors

Citation

Kanayama Y, Kaneko A, Takahashi N, et al
SAT0174 Use of a 8-week observational period for predicting remission and low disease activity at 52 weeks in ra patients treated with certolizumab pegol – a multicenter study
Annals of the Rheumatic Diseases 2017;76:835-836.

Publication history

  • First published June 15, 2017.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions